Proteolytic Origin of the Soluble Human IL-6R In Vivo and a Decisive Role of N-Glycosylation

PLoS Biology

Volumn 15, Issue 1, 2017, Pages

  Riethmueller, Steffen ^a   Somasundaram, Prasath ^a   Ehlers, Johanna C ^a   Hung, Chien Wen ^a   Flynn, Charlotte M ^a   Lokau, Juliane ^a   Agthe, Maria ^a   Düsterhöft, Stefan ^a,c   Zhu, Yijue ^a   Grötzinger, Joachim ^a   Lorenzen, Inken ^a   Koudelka, Tomas ^a   Yamamoto, Kosuke ^a,d   Pickhinke, Ute ^a   Wichert, Rielana ^a   Becker Pauly, Christoph ^a   Rädisch, Marisa ^b   Albrecht, Alexander ^b   Hessefort, Markus ^b   Stahnke, Dominik ^b   Unverzagt, Carlo ^b   Rose John, Stefan ^a   Tholey, Andreas ^a   Garbers, Christoph ^a   more..

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF BAYREUTH   (Germany)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d FUJIREBIO INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM10 ENDOPEPTIDASE; INTERLEUKIN 6 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; ADAM10 PROTEIN, HUMAN; ADAM17 PROTEIN, HUMAN; MEMBRANE PROTEIN; MESSENGER RNA; POLYSACCHARIDE; PROLINE; SECRETASE; VALINE;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; GLYCOSYLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOSITY; HUMAN; HUMAN CELL; IMMUNOREGULATION; IN VIVO STUDY; INTERNALIZATION; MUTATIONAL ANALYSIS; PLASMID; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN GLYCOSYLATION; PROTEIN PURIFICATION; PROTEIN STABILITY; PROTEIN TRANSPORT; SEQUENCE ALIGNMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM MASS SPECTROMETRY; UBIQUITINATION; ALTERNATIVE RNA SPLICING; AMINO ACID SEQUENCE; BLOOD; CELL LINE; CELL MEMBRANE; CHEMISTRY; GENETICS; INTRACELLULAR SPACE; MASS SPECTROMETRY; METABOLISM; MUTATION; SIGNAL TRANSDUCTION; SOLUBILITY;

ADAM10 PROTEIN; ADAM17 PROTEIN; ALTERNATIVE SPLICING; AMINO ACID SEQUENCE; AMYLOID PRECURSOR PROTEIN SECRETASES; CELL LINE; CELL MEMBRANE; GLYCOSYLATION; HUMANS; INTRACELLULAR SPACE; MASS SPECTROMETRY; MEMBRANE PROTEINS; MUTATION; POLYSACCHARIDES; PROLINE; PROTEIN DOMAINS; PROTEIN TRANSPORT; PROTEOLYSIS; RECEPTORS, INTERLEUKIN-6; RNA, MESSENGER; SIGNAL TRANSDUCTION; SOLUBILITY; VALINE;

EID: 85011850275     PISSN: 15449173     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.2000080     Document Type: Article

References (63)

1. Scheller J, Garbers C, Rose-John S, Interleukin-6: From basic biology to selective blockade of pro-inflammatory activities. Semin Immunol. 2014;26(1):2–12. doi: 10.1016/j.smim.2013.11.00224325804
2. Wolf J, Rose-John S, Garbers C, Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine. 2014;70(1):11–20. doi: 10.1016/j.cyto.2014.05.02424986424
3. Garbers C, Hermanns H, Schaper F, Müller-Newen G, Grötzinger J, Rose-John S, et al. Plasticity and cross-talk of Interleukin 6-type cytokines. Cytokine Growth Factor Rev. 2012;23(3):85–97. doi: 10.1016/j.cytogfr.2012.04.00122595692
4. Garbers C, Aparicio-Siegmund S, Rose-John S, The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition. Curr Opin Immunol. 2015;34:75–82. doi: 10.1016/j.coi.2015.02.00825749511
5. Garbers C, Scheller J, Interleukin-6 and interleukin-11: same same but different. Biol Chem. 2013;394(9):1145–61. doi: 10.1515/hsz-2013-016623740659
6. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S, The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813(5):878–88. doi: 10.1016/j.bbamcr.2011.01.03421296109
7. Baran P, Nitz R, Grötzinger J, Scheller J, Garbers C, Minimal interleukin (IL-)6 receptor stalk composition for IL-6R shedding and IL-6 classic signaling. J Biol Chem. 2013;288(21):14756–68. doi: 10.1074/jbc.M113.46616923564454
8. Mitra N, Sinha S, Ramya TN, Surolia A, N-linked oligosaccharides as outfitters for glycoprotein folding, form and function. Trends Biochem Sci. 2006;31(3):156–63. doi: 10.1016/j.tibs.2006.01.00316473013
9. Waetzig GH, Chalaris A, Rosenstiel P, Suthaus J, Holland C, Karl N, et al. N-linked glycosylation is essential for the stability but not the signaling function of the interleukin-6 signal transducer glycoprotein 130. J Biol Chem. 2010;285(3):1781–9. doi: 10.1074/jbc.M109.07595219915009
10. Slieker LJ, Lane MD, Post-translational processing of the epidermal growth factor receptor. Glycosylation-dependent acquisition of ligand-binding capacity. J Biol Chem. 1985;260(2):687–90. 2981842
11. Ding DXH, Vera JC, Heaney ML, Golde DW, N-glycosylation of the human granulocyte-macrophage colony-stimulating factor receptor α subunit is essential for ligand binding and signal transduction. J Biol Chem. 1995;270(41):24580–4. 7592677
12. Zhou H, Tai HH, Characterization of recombinant human CXCR4 in insect cells: role of extracellular domains and N-glycosylation in ligand binding. Arch Biochem Biophys. 1999;369(2):267–76. doi: 10.1006/abbi.1999.136810486146
13. Cole AR, Hall NE, Treutlein HR, Eddes JS, Reid GE, Moritz RL, et al. Disulfide bond structure and N-glycosylation sites of the extracellular domain of the human interleukin-6 receptor. J Biol Chem. 1999;274(11):7207–15. 10066782
14. Müllberg J, Oberthür W, Lottspeich F, Mehl E, Dittrich E, Graeve L, et al. The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. J Immunol. 1994;152(10):4958–68. 8176214
15. Jones SA, Scheller J, Rose-John S, Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest. 2011;121(9):3375–83. doi: 10.1172/JCI5715821881215
16. Horiuchi S, Koyanagi Y, Zhou Y, Miyamoto H, Tanaka Y, Waki M, et al. Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur J Immunol. 1994;24(8):1945–8. doi: 10.1002/eji.18302408378056053
17. Müller-Newen G, Kohne C, Keul R, Hemmann U, Müller-Esterl W, Wijdenes J, et al. Purification and Characterization of the Soluble Interleukin-6 Receptor from Human Plasma and Identification of An Isoform Generated through Alternative Splicing. Eur J Biochem. 1996;236(3):837–42. 8665902
18. Horiuchi S, Ampofo W, Koyanagi Y, Yamashita A, Waki M, Matsumoto A, et al. High-level production of alternatively spliced soluble interleukin-6 receptor in serum of patients with adult T-cell leukaemia/HTLV-I-associated myelopathy. Immunology. 1998;95(3):360–9. 9824498
19. Leggate M, Nowell MA, Jones SA, Nimmo MA, The response of interleukin-6 and soluble interleukin-6 receptor isoforms following intermittent high intensity and continuous moderate intensity cycling. Cell Stress Chaperones. 2010;15(6):827–33. doi: 10.1007/s12192-010-0192-z20396982
20. Dimitrov S, Lange T, Benedict C, Nowell MA, Jones SA, Scheller J, et al. Sleep enhances IL-6 trans-signaling in humans. FASEB J. 2006;20(12):2174–6. doi: 10.1096/fj.06-5754fje16912152
21. Garbers C, Monhasery N, Aparicio-Siegmund S, Lokau J, Baran P, Nowell MA, et al. The Interleukin-6 Receptor Asp358Ala Single Nucleotide Polymorphism rs2228145 Confers Increased Proteolytic Conversion Rates by ADAM Proteases. Biochim Biophys Acta. 2014;1842(9):1485–94. doi: 10.1016/j.bbadis.2014.05.01824878322
22. Schumacher N, Meyer D, Mauermann A, von der Heyde J, Wolf J, Schwarz J, et al. Shedding of Endogenous Interleukin-6 Receptor (IL-6R) Is Governed by A Disintegrin and Metalloproteinase (ADAM) Proteases while a Full-length IL-6R Isoform Localizes to Circulating Microvesicles. J Biol Chem. 2015;290(43):26059–71. doi: 10.1074/jbc.M115.64950926359498
23. Tucher J, Linke D, Koudelka T, Cassidy L, Tredup C, Wichert R, et al. LC-MS based cleavage site profiling of the proteases ADAM10 and ADAM17 using proteome-derived peptide libraries. J Proteome Res. 2014;13(4):2205–14. doi: 10.1021/pr401135u24635658
24. Rawlings ND, Waller M, Barrett AJ, MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res. 2013;42:D503–9. doi: 10.1093/nar/gkt95324157837
25. Goth CK, Halim A, Khetarpal SA, Rader DJ, Clausen H, Schjoldager TK, A systematic study of modulation of ADAM-mediated ectodomain shedding by site-specific O-glycosylation. Proc Natl Acad Sci U S A. 2015;112(47):14623–8. doi: 10.1073/pnas.151117511226554003
26. Düsterhöft S, Höbel K, Oldefest M, Lokau J, Waetzig GH, Chalaris A, et al. A disintegrin and metalloprotease 17 dynamic interaction sequence, the sweet tooth for the human interleukin 6 receptor. J Biol Chem. 2014;289(23):16336–48. doi: 10.1074/jbc.M114.55732224790088
27. Garbers C, Jänner N, Chalaris A, Moss ML, Floss DM, Meyer D, et al. Species specificity of ADAM10 and ADAM17 proteins in interleukin-6 (IL-6) trans-signaling and novel role of ADAM10 in inducible IL-6 receptor shedding. J Biol Chem. 2011;286(17):14804–11. doi: 10.1074/jbc.M111.22939321454673
28. Althoff K, Müllberg J, Aasland D, Voltz N, Kallen K, Grötzinger J, et al. Recognition sequences and structural elements contribute to shedding susceptibility of membrane proteins. Biochem J. 2001;353(Pt 3):663–72. 11171064
29. Novick D, Engelmann H, Wallach D, Rubinstein M, Soluble cytokine receptors are present in normal human urine. J Exp Med. 1989;170(4):1409–14. 2529343
30. Honda M, Yamamoto S, Cheng M, Yasukawa K, Suzuki H, Saito T, et al. Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. J Immunol. 1992;148(7):2175–80. 1545125
31. Chalaris A, Rabe B, Paliga K, Lange H, Laskay T, Fielding CA, et al. Apoptosis is a natural stimulus of IL6R shedding and contributes to the pro-inflammatory trans-signaling function of neutrophils. Blood. 2007;110:1748–55. doi: 10.1182/blood-2007-01-06791817567983
32. Schnölzer M, Jedrzejewski P, Lehmann WD, Protease-catalyzed incorporation of 18O into peptide fragments and its application for protein sequencing by electrospray and matrix-assisted laser desorption/ionization mass spectrometry. Electrophoresis. 1996;17(5):945–53. doi: 10.1002/elps.11501705178783021
33. Matthews V, Schuster B, Schutze S, Bussmeyer I, Ludwig A, Hundhausen C, et al. Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem. 2003;278(40):38829–39. doi: 10.1074/jbc.M21058420012832423
34. Lokau J, Nitz R, Agthe M, Monhasery N, Aparicio-Siegmund S, Schumacher N, et al. Proteolytic Cleavage Governs Interleukin-11Trans-signaling. Cell Rep. 2016;14(7):1761–73. doi: 10.1016/j.celrep.2016.01.05326876177
35. Bank U, Reinhold D, Schneemilch C, Kunz D, Synowitz H, Ansorge S, Selective proteolytic cleavage of IL-2 receptor and IL-6 receptor ligand binding chains by neutrophil-derived serine proteases at foci of inflammation. J Interferon Cytokine Res. 1999;19(11):1277–87. doi: 10.1089/10799909931295710574621
36. Jones S, Horiuchi S, Novick D, Yamamoto N, Fuller G, Shedding of the soluble IL-6 receptor is triggered by Ca2+ mobilization, while basal release is predominantly the product of differential mRNA splicing in THP-1 cells. Eur J Immunol. 1998;28(11):3514–22. doi: 10.1002/(SICI)1521-4141(199811)28:1160;3514::AID-IMMU351462;3.0.CO;2-T9842894
37. Rafiq S, Frayling T, Murray A, Hurst A, Stevens K, Weedon M, et al. A common variant of the interleukin 6 receptor (IL-6r) gene increases IL-6r and IL-6 levels, without other inflammatory effects. Genes Immun. 2007;8(7):552–9. doi: 10.1038/sj.gene.636441417671508
38. Galicia J, Tai H, Komatsu Y, Shimada Y, Akazawa K, Yoshie H, Polymorphisms in the IL-6 receptor (IL-6R) gene: strong evidence that serum levels of soluble IL-6R are genetically influenced. Genes Immun. 2004;5(6):513–6. doi: 10.1038/sj.gene.636412015306846
39. Mohan MJ, Seaton T, Mitchell J, Howe A, Blackburn K, Burkhart W, et al. The tumor necrosis factor-alpha converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity. Biochemistry. 2002;41(30):9462–9. 12135369
40. Lorenzen I, Lokau J, Düsterhoft S, Trad A, Garbers C, Scheller J, et al. The membrane-proximal domain of A Disintegrin and Metalloprotease 17 (ADAM17) is responsible for recognition of the interleukin-6 receptor and interleukin-1 receptor II. FEBS Lett. 2012;586(8):1093–100. doi: 10.1016/j.febslet.2012.03.01222575642
41. Aderka D, Englemann H, Hornik V, Skornick Y, Levo Y, Wallach D, et al. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res. 1991;51(20):5602–7. 1655258
42. Siebert S, Tsoukas A, Robertson J, McInnes I, Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. Pharmacological Rev2015;67(2):280–309.
43. Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN, et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;379(9822):1205–13. doi: 10.1016/S0140-6736(11)61931-422421339
44. Swerdlow D, Holmes M, Kuchenbaecker K, Engmann J, Shah T, Sofat R, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379(9822):1214–24. doi: 10.1016/S0140-6736(12)60110-X22421340
45. Stone K, Woods E, Szmania SM, Stephens OW, Garg TK, Barlogie B, et al. Interleukin-6 Receptor Polymorphism Is Prevalent in HIV-negative Castleman Disease and Is Associated with Increased Soluble Interleukin-6 Receptor Levels. PLoS ONE. 2013;8(1):e54610. doi: 10.1371/journal.pone.005461023372742
46. Takakura-Yamamoto R, Yamamoto S, Fukuda S, Kurimoto M, O-glycosylated species of natural human tumor-necrosis factor-alpha. Eur J Biochem. 1996;235(1–2):431–7. 8631363
47. Bringman TS, Lindquist PB, Derynck R, Different transforming growth factor-alpha species are derived from a glycosylated and palmitoylated transmembrane precursor. Cell. 1987;48(3):429–40. 3467848
48. Minond D, Cudic M, Bionda N, Giulianotti M, Maida L, Houghten RA, et al. Discovery of Novel Inhibitors of a Disintegrin and Metalloprotease 17 (ADAM17) Using Glycosylated and Non-glycosylated Substrates. J Biol Chem. 2012;287(43):36473–87. doi: 10.1074/jbc.M112.38911422927435
49. Fischer M, Goldschmitt J, Peschel C, Brakenhoff JP, Kallen KJ, Wollmer A, et al. I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol. 1997;15(2):142–5. doi: 10.1038/nbt0297-1429035138
50. Vollmer P, Oppmann B, Voltz N, Fischer M, Rose-John S, A role for the immunoglobulin-like domain of the human IL-6 receptor. Intracellular protein transport and shedding. FEBS J. 1999;263(2):438–46.
51. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC, Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science. 2003;300(5628):2101–4. doi: 10.1126/science.108390112829785
52. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature. 1994;370:555–7. doi: 10.1038/370555a08052310
53. Kovaleva M, Bussmeyer I, Rabe B, Grötzinger J, Sudarman E, Eichler J, et al. Abrogation of viral interleukin-6 (vIL-6)-induced signaling by intracellular retention and neutralization of vIL-6 with an anti-vIL-6 single-chain antibody selected by phage display. J Virol. 2006;80(17):8510–20. doi: 10.1128/JVI.00420-0616912301
54. Fischer M, Goldschmitt J, Peschel C, Brakenhoff JP, Kallen KJ, Wollmer A, et al. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotech. 1997;15(2):145–5.
55. Schroers A, Hecht O, Kallen KJ, Pachta M, Rose-John S, Grotzinger J, Dynamics of the gp130 cytokine complex: a model for assembly on the cellular membrane. Protein Sci. 2005;14(3):783–90. doi: 10.1110/ps.04111710515722452
56. Mackiewicz A, Schooltink H, Heinrich PC, Rose-John S, Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol. 1992;149(6):2021–7. 1381393
57. Ketteler R, Glaser S, Sandra O, Martens UM, Klingmuller U, Enhanced transgene expression in primitive hematopoietic progenitor cells and embryonic stem cells efficiently transduced by optimized retroviral hybrid vectors. Gene Ther. 2002;9(8):477–87. doi: 10.1038/sj.gt.330165311948372
58. Garbers C, Thaiss W, Jones GW, Waetzig GH, Lorenzen I, Guilhot F, et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem. 2011;286(50):42959–70. doi: 10.1074/jbc.M111.29575821990364
59. Suthaus J, Tillmann A, Lorenzen I, Bulanova E, Rose-John S, Scheller J, Forced homo- and heterodimerization of all gp130-type receptor complexes leads to constitutive ligand-independent signaling and cytokine-independent growth. Mol Biol Cell. 2010;21(15):2797–807. doi: 10.1091/mbc.E10-03-024020554759
60. Somasundaram P, Koudelka T, Linke D, Tholey A, C-Terminal Charge-Reversal Derivatization and Parallel Use of Multiple Proteases Facilitates Identification of Protein C-Termini by C-Terminomics. J Proteome Res. 2016;15(4):1369–78. doi: 10.1021/acs.jproteome.6b0014626939532
61. Wu Z, Guo X, Guo Z, Chemoenzymatic synthesis of glycosylphosphatidylinositol-anchored glycopeptides. Chem Commun. 2010;46(31):5773–4.
62. Ullmann V, Rädisch M, Boos I, Freund J, Pöhner C, Schwarzinger S, et al. Convergent solid-phase synthesis of N-glycopeptides facilitated by pseudoprolines at consensus-sequence Ser/Thr residues. Angew Chem Int Ed Engl. 2012;51(46):11566–70. doi: 10.1002/anie.20120427222945377
63. Chen R, Tolbert TJ, Study of on-resin convergent synthesis of N-linked glycopeptides containing a large high mannose N-linked oligosaccharide. J Am Chem Soc. 2010;132(9):3211–6. doi: 10.1021/ja910407320158247